About the Summit

2024 Honorary Advisors

ASGH Brochure

ASGH Webinar and Seminar Series

Join ASGH Community

Previous Summit

Contact Us

ABOUT ASGH

Registration

2024 Speakers

2024 Programme

Sponsors and Partners

ASGH Deal-making

Exhibitors

InnoHealth Showcase

ASGH Side Trip

House Rules

Special Airfares From Cathy Pacific

Green Tips

Arrangement for Inclement Weather

EVENT DETAILS

Press Releases

Video Gallery

Photo Gallery

MEDIA

Biotech, Medical & Healthcare Industry in Hong Kong

Market Profile of Hong Kong

Case Studies and News

International Healthcare Week

INTELLIGENCE

HOMEPAGE

ABOUT THE SUMMIT

ASGH BROCHURE

PREVIOUS SUMMIT

GENERAL ENQUIRIES

REGISTRATION

2023 SPONSORS, GLOBAL AFFILIATE PARTNERS AND SUPPORTING MEDIA

EXHIBITION AND GOVERNMENT FUNDING

Business of Healthcare Advisory Zone

PRESS RELEASES

VIDEO GALLERY 2021

JOIN ASGH COMMUNITY

Hygiene Measures & Health Tips for Participants

BIOTECH, MEDICAL & HEALTHCARE INDUSTRY IN HONG KONG

PHOTO GALLERY 2021

CASE STUDIES AND NEWS

PROGRAMME HIGHLIGHTS

Travel to Hong Kong

Welcome Message

PHOTO GALLERY 2022

VIDEO GALLERY 2023

Asia Summit on Global Health 2022

Programme

SPECIAL AIRFARES FROM CATHAY PACIFIC

webinar testing

Programme 2022

Speaker 2022

Participants 2022

GREEN TIPS

PHOTO GALLERY

Asia Summit on Global Health 2023

Programme 2023

Speaker 2023

Participants 2023

VIDEO GALLERY 2022

PHOTO GALLERY 2023

Exhibitor and Affiliate Partner

Honorary Advisors

VIDEO GALLERY

Asia Summit on Global Health 2024

Speaker

participant list

Opening Session

Hong Kong Trade Development Council

Dr Peter K N Lam, GBM, GBS

Chairman

WELCOME REMARKS

Hong Kong Special Administrative Region of the People's Republic of China

The Hon John KC Lee, GBM, SBS, PDSM, PMSM

The Chief Executive

OPENING REMARKS

National Health Commission of the People's Republic of China

Prof Cao Xuetao

Vice-Minister

SPECIAL REMARKS

World Health Organization

Dr Tedros Adhanom Ghebreyesus

Director-General

PRE–RECORDED SPECIAL REMARKS

Hong Kong is determined to leverage its medical strengths &ndash; grounded with high-quality medical care and an efficient healthcare system &ndash; to establish the Centre for Medical Products Regulation (CMPR) that registers drugs and medical devices under the &quot;primary evaluation&quot; approach and develop as a health and medical innovation hub.With this development, more pharmaceutical and medical device enterprises from around the world are expected to conduct R&amp;D and clinical trials in Hong Kong which would help create a more synergistic ecosystem for medical innovations.Our panel of pharmaceutical regulatory experts, academia and industry leaders will elaborate on mainland and overseas drug approval experience, ways to nurture innovation talents, and explore business opportunities arising from the &ldquo;primary evaluation&rdquo; regime.

Plenary Session I – Unleashing Opportunities: Co-create a Synergistic Ecosystem for Health Innovation

Hong Kong Special Administrative Region of the People’s Republic of China

Prof Lo Chung-mau, BBS, JP

Secretary for Health

SPECIAL REMARKS – DEVELOPING HONG KONG INTO A HEALTH AND MEDICAL INNOVATION HUB

Ministry of Industry and Information Technology of the People's Republic of China

Mr He Yaqiong

Director General of Consumer Goods Industry Department,

The University of Hong Kong

Prof Lau Chak-sing

Dean of Medicine

PANEL CHAIR

Chairman, Evergreen Biopharmaceuticals Limited

Dr Tom Du

Chairman-Elected, PhIRDA International Regulatory Science Specialty Committee;

HK Bio-Med Innotech Association

Prof Lo Yuk Lam, BBS

President

Luye Pharma Group Ltd.

Dr Sun Zhigang

Senior Vice President

Co-founder and Co-chairman, Jiangsu Hillgene Biopharma Co.,Ltd

Dr Zhang Dan

Co-founder and CSO, ClinChoice;

SPEAKERS

Cooperation Agreements Signing Ceremony

To explore the role of emerging technologies and collaborative efforts in revolutionising healthcare and promoting inclusivity, this session features a keynote session by Nobel Prize-winning American biochemist Professor Roger Kornberg, followed by a thought-provoking panel discussion among renowned figures and stakeholders of the broader healthcare ecosystem.With the latest innovative R&amp;D in transforming healthcare goals to improve health with new products and processes, what market opportunities are presented for global professionals and business players?Our panel of healthcare industry leaders &ndash; from academia and healthcare service providers to pharmaceutical and health-tech companies to venture investor and entrepreneur &ndash; comes together to provide insights on how new technologies hold the potential to transform healthcare delivery and offer alternative treatments and cures. The panel also examines the strategies to address healthcare disparities by ensuring diverse access to innovative solutions, and the significance of effective collaboration among stakeholders in making a lasting impact on healthcare innovation and inclusivity.

Plenary Session II – Innovation．Inclusion．Impact

Stanford University School of Medicine

Prof Roger Kornberg

Nobel Laureate in Chemistry 2006; Mrs. George A. Winzer Professor in Medicine & Professor of Structural Biology

KEYNOTE SESSION – DIAGNOSIS AND DRUG DELIVERY – NEW TECHNOLOGIES IN BIOTECH

First Eastern Investment Group

Mr Victor L L Chu

Chairman & CEO

Thrive Bioscience, Inc.

Mr Thomas Farb-Horch

CEO and President

Philips Greater China

Mr Andy Ho

Chief Region Leader

EC Healthcare

Mr Leslie Lu

Executive Director and CEO

Sino Biopharmaceutical Limited

Ms Theresa Tse

Chairwoman of the Board

Networking Break

Powered by HKU Techno-Entrepreneurship Core

MedTech Hackathon Hong Kong 2024 Final Pitch and Award Ceremony

This one-on-one fireside chat on latest trends and findings in neurology is with Professor Michael Hanna, Director of the UCL Institute of Neurology and senior consultant neurologist at the UK&rsquo;s National Hospital for Neurology and Neurosurgery (NHNN) in London.Professor Hanna is a celebrated neurologist specialising in the diagnosis, treatment and care of patients with various neurological conditions affecting the brain, spinal cord, nervous system and muscles &ndash; causing pain, muscle weakness, memory loss and speech difficulties.With over 25 years&rsquo; clinical experience, he has personally assessed over 30,000 patients, and published over 400 articles&nbsp;sharing his expert research with the medical community worldwide.His expertise extends from common neurological symptoms such as headaches, blackouts and strokes to an international reputation as a leading authority in diagnosing and treating patients with muscle weakness caused by neuromuscular diseases.Dedicated to advancing understanding and developing innovative treatments, Professor Hanna has received numerous research awards and grants funding vital research to find treatments and cures for neurological conditions.

Dialogue with Global Pioneer in Health

MODERATOR

University College London

Prof Michael Hanna

Director of UCL Queen Square Institute of Neurology

SPEAKER

The healthcare sector in China is experiencing a significant acceleration in recent years, especially in response to the growing demand for more specialised and high-quality healthcare arising from the rapidly ageing population. The Chinese government is taking necessary steps towards more care and higher standards, from establishing a healthcare insurance system to investment in new hospitals, clinics and advancing medical technology &ndash; such as AI-powered diagnosis, digital record storage for sharing patient data, and a booming telemedicine sector.With China&rsquo;s healthcare industry targeted to grow by 50% by 2030, our panel of industry leaders explains the latest healthcare development and the current investment landscape in Mainland China. They also examine the potential and opportunity to international investors for collaborations, knowledge exchange and partnerships crucial to driving excellence.

What’s Next in China’s Healthcare Arena

The Chinese University of Hong Kong

Prof Tony Mok Shu Kam, BBS

Chairman of Department of Clinical Oncology

Group Chairman & Co-Founder, New Frontier Group

Mr Antony Leung

Group Chairman, Nan Fung Group;

AXA Greater China

Ms Sally Wan

CanSino Biologics Inc.

Dr Yu Xuefeng

Co-founder, Chief Executive Officer and Chairman

Collaborations among stakeholders in the healthcare ecosystem are expediting innovation for next-generation healthcare products and medical procedures. Emerging technologies, such as digital health and artificial intelligence (AI) are playing increasingly crucial roles in the field.What business partnership opportunities lie ahead in health innovation and collaboration? What latest digital advancements investors should investors eye on? How can global players leverage the resources and advantages of this vibrant ecosystem to achieve their business success?Our international panel of distinguished health business leaders discusses the latest market trends and the generational shift inspiring dynamic change &ndash; exploring collaboration opportunities between universities, hospitals, health innovators and financial institutions to accelerate and commercialise solutions for evolving needs.

Fostering Collaboration for Next-Gen Healthcare Business

The Hong Kong Polytechnic University

Prof Christopher Chao

Vice President (Research and Innovation)

Fosun Health Group

Mr Hu Hang

China Meheco Group Co. Ltd

Ms Hu Huidong

Director and General Manager

Pureos Partners AG

Dr Martin Münchbach

Managing Director

HSBC

Ms Anita Ou

Managing Director, Head of Enterprise Banking, Commercial Banking, Hong Kong

Harrison.ai / Annalise.ai

Mr Dimitry Tran

Co-Founder

A stark divide in global access to healthcare was highlighted during the pandemic, revealing continuing challenges of low-and middle-income countries in accessing basic, essential healthcare products &mdash; let alone latest medicines and cutting-edge treatments.But investors have the power to bolster health equity globally while still generating value through impact investing &mdash; providing financial returns while also making a positive social or environmental impact.The term &ldquo;impact investing&rdquo; has grown into a movement by demonstrating that investing for returns is not mutually exclusive from doing good.In fact, by focusing on impact and pursuing more sustainable models, investors often set themselves up for longer-term profitability. In a 2020 survey by the Global Impact Investing Network, 88% of respondents reported that their impact investments met or exceeded their financial expectations.Examining the current landscape of healthcare in various regions, our international panel of bioscience entrepreneur and investment specialists pinpoints specific examples of leveraging private capital to address challenges facing the world today &ndash; and attractive investment opportunities that also improve access, quality and affordability of healthcare worldwide.

Healthcare Investment Making Positive Impact

Sino Group

Ir Andrew Young

Associate Director (Innovation)

Vice President, Swiss Biotech Association

Dr Bettina Ernst

Director, Bernina BioInvest Ltd;

Novo Holdings Asia

Dr Amit Kakar

Managing Partner and Head of Asia

China Renaissance

Mr Kevin Xie

Chairman, Chief Executive Officer

Project Pitching: Themed Session 1 - AI & Digital Health

Artificial intelligence (AI) is reshaping healthcare, increasing speed of diagnosis with higher accuracy of medical tests while improving patient outcomes.The rapid emergence of AI is also fuelled by demand for tailored healthcare solutions at lower costs &ndash; applied across healthcare from remote patient care&nbsp;to robots in operating rooms; faster drug development and analysis of medical images; and early detection of severe diseases such as cancer.With global market valuation of US$15 billion in 2022, its&nbsp;projected value is more than US$187 billion by 2030.Yet AI remains burdened by a legacy of suspicion, obliging healthcare organisations and tech companies to re-assure the technology is used responsibly and ethically to address many of the challenges ahead.In this session, our international panel of AI industry leaders examines those challenges and also explores opportunities, including integrating AI in medical devices, tailored healthcare, innovative AI solutions and future trends.